Shattuck Labs, Inc. Common Stock (STTK)
Shattuck Labs, Inc. is a biotechnology company focused on developing innovative therapeutics that modulate the immune system. The company leverages its proprietary SIRPα-Fc fusion protein platform to create targeted therapies aimed at treating cancer and autoimmune diseases. Founded to advance immune-modulating agents, Shattuck Labs emphasizes precision medicine approaches in its drug development pipelines.
Company News
Shattuck Labs, a biotechnology company, announced that its CEO will present at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025. The company's lead program, SL-325, is a potential first-in-class DR3 antagonist antibody designed to treat inflammatory and immune-mediated diseases.
Stay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
During the last three months, 6 analysts shared their evaluations of Shattuck Labs (NASDAQ:STTK), revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indiff...